Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
The role of T cell apoptosis in nervous system autoimmunity.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Optimizing IFN Beta - 1B Dose (Optims)
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
HL-A antigens and multiple sclerosis.
Pages
« first
‹ previous
…
80
81
82
83
84
85
86
87
88
…
next ›
last »